{"id":"W2424539745","doi":"10.1056/nejmoa1515920","title":"Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes","year":2016,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3629,"is_retracted":false,"has_abstract":true,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"","keywords":"Empagliflozin; Medicine; Placebo; Hazard ratio; Internal medicine; Diabetes mellitus; Albuminuria; Renal function; Type 2 diabetes; Diabetic nephropathy; Creatinine; Kidney disease; Urology; Surgery; Confidence interval; Endocrinology; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}